The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

A Yemeni molecular biologist Hashem Al-Ghaili, shared a post on his Instagram page that states that the new K-variant flu, also known as the super flu is spreading fast "with dangerous fevers and lung damage". On his post, he wrote: "Health experts say there‘s a new flu strain causing sudden high fevers and deep respiratory distress."

He further noted: "Public health officials are sounding the alarm over a potent new influenza strain that behaves differently than previous seasonal variants. Rather than just causing typical fatigue, this aggressive strain is designed to trick the human immune system into a state of hyper-reactivity. This overreaction often manifests as sudden, intense fever spikes and significant inflammation deep within the lung tissue. Unlike standard flu symptoms that may develop gradually, these severe respiratory complications are appearing with alarming speed, making early detection and prevention more critical than ever before."

To this, he also provided a solution, stating that medical professionals are now emphasizing on the importance of fortifying "body's natural defenses through foundational wellness habits". These habits include prioritizing deep sleep, consistent hydration, and adequate vitamin D intake that can help regulate immune responses and mitigate the risk of severe inflammation.

Read: UK ‘Super Flu’ May Be Behind Sudden Bile Vomiting; Doctors Flag New Symptom

What Is The K-Variant Flu And How Does It Impact Your Lungs?

H3N2's mutation or the influenza A's subclade K is now the new aggressive virus that has swept the United States and the United Kingdom with flu cases. This is the culprit in rising flu cases, globally. The World Health Organization (WHO) on its website said that K variant marks "a notable evolution in influenza A (H3N2) viruses". Some are also questioning the effectiveness of this season's influenza vaccine against the strain.

The flu virus is highly contagious and spreads easily in crowded places, especially during the colder months.

In some cases, the infection can progress to the lungs, which could lead to complications like bronchitis or pneumonia. Yale Medicine too notes that this virus could attack the respiratory system, including throat, nose, and lungs.

What Are The Common Symptoms This Season For The Flu?

K variant causes more intense flu symptoms, they include:

• Fever
• Chills
• Headache
• Fatigue
• Cough
• Sore throat
• Runny nose

Are The Old Vaccines Effective Against This New Variant?

"The vaccine remains the most effective means to prevent disease. We still want to encourage people to get the vaccine," said Professor Antonia Ho, Professor and Honorary Consultant in Infectious Diseases at the University of Glasgow. Experts have stressed enough on the immunity that one can receive from the vaccine that that these flu jab remain the best defense against the flu, even though the current strain circulated may have drifted away from the strain included in this year's jab.

Data from the UK Health Security Agency (UKHSA) also show that vaccines is performing as expect, despite the emergence of subclade K.

SMA-1. a rare disease, known as the spinal muscular atrophy type 1 or the Werdnig-Hoffmann disease is when the muscle weakness appears at birth or within the first six months. This rare condition prevents infants from sitting unassisted and causing severe breathing, swallowing, and sucking difficulties, leading to a poor prognosis without aggressive support. This condition has impacted the twin babies of the former Little Mix singer Jesy Nelson. Her twin babies may never be able to walk. However, she said that her babies will "fight all the odds" after they were being diagnosed with such a rare genetic condition.

Also Read: 'Eat Ice-cream' Says Dr Ezekiel Emanuel, Along With Other Simple Tricks To Live A Long And Healthy Life

Nelson, 34, and her fiancé, Zion Foster welcomed their twins, Ocean Jade and Story Monroe Nelson-Foster in May, when they were both born prematurely. In an emotional Instagram video, posted on Sunday, Nelson revealed the diagnosis her twin babies had.

“We were told that they’re probably never going to be able to walk; they probably will never regain their neck strength, so they will be disabled, and so the best thing we can do right now is to get them treatment, and then just hope for the best,” she said.

“Thankfully, the girls have had their treatment, which you know, I’m so grateful for because if they don’t have it, they will die," she further said.

Nelson's babies were diagnosed four months of, what she said, "gruelling" hospital appointments, and so she wanted to raise awareness of the condition and the signs one should look out for because "time is of the essence" with the condition.

“I just think that I can raise as much awareness about this as possible, and the signs, then, you know, something good has to come out of this,” said Nelson.

Read: SMA Type 1: What This Health Condition Could Mean For Jesy Nelson’s Babies’ Mobility

Jesy Nelson Twins: What Are The Signs of SMA-1?

Nelson said that there could be some common signs to look out for, which includes floppiness, inability to hold yourself up without support, a "frog-like" positioning of the legs without much movement, and rapid breathing in the tummy.

"If anyone is watching this video and they think they see these signs in their child, then please, please take your child to the doctor, to the hospital, because time is of the essence, and your child will need treatment. And the quicker you get this, the better their life will be," she added.

What Are The Other Types Of SMA?

There are five recognized subtypes of SMA, classified by the age symptoms appear, severity, and expected life span:

SMA Type 0 (congenital SMA): This extremely rare form appears before birth, with reduced fetal movement. Newborns often show severe muscle weakness and usually experience respiratory failure, with death occurring at birth or within the first month.

SMA Type 1 (severe SMA): This accounts for roughly 60% of SMA cases and is also called Werdnig-Hoffman disease. Symptoms start within the first six months, including weak head control and low muscle tone (hypotonia). Infants may struggle to swallow and breathe, and without respiratory support, life expectancy is typically under two years.

SMA Type 2 (intermediate SMA): Also called Dubowitz disease, symptoms appear between six and 18 months. Muscle weakness worsens over time, usually affecting the legs more than the arms. Children may sit but cannot walk. Around 70% survive into their mid-20s, with respiratory complications being the main cause of death.

SMA Type 3 (mild): Known as Kugelbert-Welander disease, this type appears after 18 months. Weakness primarily affects the legs, making walking difficult, but breathing issues are rare, and life expectancy is generally unaffected.

SMA Type 4 (adult): The mildest form, it appears after age 21. Muscle weakness progresses slowly, and most people remain mobile, with normal life expectancy.

A deadly fungus that resists multiple drugs is already spreading quickly through hospitals in the U.S. and is becoming an increasing concern worldwide, though there may be some hope for new treatments, according to a recent scientific review.

Candida auris (C. auris), often called a "superbug fungus," is spreading across the globe and becoming harder for the human immune system to fight, researchers at the Hackensack Meridian Center for Discovery and Innovation (CDI) noted in a review published in early December.

The findings echo previous CDC warnings that classified C. auris as an "urgent antimicrobial threat" — the first fungal pathogen to earn this label, as U.S. cases have risen sharply, particularly in hospitals and long-term care facilities.

Superbug Fungus: Dangerous Spike in Superbug Infections Across the U.S.

According to the CDC, roughly 7,000 cases were reported across dozens of U.S. states in 2025, and the fungus has now been identified in at least 60 countries.

The review, published in Microbiology and Molecular Biology Reviews, explains why the pathogen is so difficult to contain and highlights that outdated diagnostic tools and limited treatment options lag behind its rapid spread. Researchers involved included Dr. Neeraj Chauhan of Hackensack Meridian CDI, Dr. Anuradha Chowdhary of the University of Delhi’s Medical Mycology Unit, and Dr. Michail Lionakis, chief of the NIH’s clinical mycology program.

The team emphasized the urgent need for “novel antifungal agents with broad activity against human fungal pathogens, improved diagnostic tests, and immune- or vaccine-based adjunct treatments for high-risk patients.” They also stressed that awareness campaigns and better surveillance, especially in resource-limited countries, are key to improving outcomes for those affected by opportunistic fungal infections.

Superbug Fungus Symptoms

The symptoms of a Candida auris infection can vary depending on which part of the body is affected. According to the Cleveland Clinic, some possible signs include:

• Fever
• Chills
• Extreme fatigue or weakness
• Low blood pressure
• Rapid heartbeat (tachycardia)
• Abnormally low body temperature (hypothermia)
• Pain, pressure, or a sense of fullness in the ear (in cases of C. auris ear infection)

Because many individuals who contract C. auris are already critically ill, the infection’s symptoms might not always be obvious. In fact, people can carry the fungus without showing any signs but still have the potential to transmit it to others.

Superbug Fungus: How C. auris Spreads

First discovered in 2009 from a patient’s ear in Japan, C. auris has now reached dozens of countries, including the U.S., where some hospital intensive care units have had to shut down due to outbreaks. The fungus is most dangerous to people who are already critically ill, particularly those on ventilators or with weakened immune systems, with some estimates suggesting up to half of infected patients may die.

Unlike many other fungi, C. auris can survive on human skin and cling to hospital surfaces and medical equipment, making it easy to spread in healthcare settings. “It is resistant to multiple antifungal drugs and tends to spread in hospitals, including on equipment used for immunocompromised patients, such as ventilators and catheters,” said Dr. Marc Siegel, senior medical analyst at Fox News and clinical professor at NYU Langone.

The fungus is often misdiagnosed, delaying treatment and infection control measures. “Symptoms like fever, chills, and aches can be mistaken for other infections,” Siegel added.

Treatment Challenges and Research Progress

Currently, only four main classes of antifungal drugs exist, and C. auris has shown resistance to many of them. While three new antifungal medications have been approved or are in late-stage trials, drug development has struggled to keep pace with the pathogen’s evolution.

Despite this, researchers remain cautiously optimistic. A study from the University of Exeter in England, published in Communications Biology, identified a potential vulnerability in the fungus. The team found that C. auris activates specific genes to scavenge iron, which it needs to survive. Drugs that block this process may eventually stop infections or allow existing medications to be repurposed.

“We may have uncovered an Achilles’ heel in this deadly pathogen during active infection,” said Dr. Hugh Gifford, co-author and clinical lecturer at the University of Exeter.

While research continues to understand and combat C. auris, health officials stress that strict infection control, rapid detection, and investment in new treatments are crucial. Importantly, C. auris is not considered a threat to healthy individuals, but it poses a serious risk to patients in hospitals and long-term care settings.